Clinical Trials
2,206 trialsNCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06820463 2026-05-27
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT07198074 2026-05-27
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07286266 2026-05-27
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT00217737 2026-05-26
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00334815 2026-05-26
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00569127 2026-05-26
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00588770 2026-05-26
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT04929223 2026-05-26
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT05445778 2026-05-26
GLORIOSA
AbbVie
Phase 3 Active not recruiting
NCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05620771 2026-05-26
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Recruiting
NCT06427239 2026-05-26
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Fudan University
Phase 1/2 Recruiting
NCT06819007 2026-05-26
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT06843447 2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06997497 2026-05-26
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07111546 2026-05-26
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07284849 2026-05-26
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT01445509 2026-05-22
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02350530 2026-05-22
FORBES
Sun Yat-sen University
Phase 2 Completed
NCT03715933 2026-05-22
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
NCT03937830 2026-05-22
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04230187 2026-05-22
TRIBE-C
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05464030 2026-05-22
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
Phase 1 Recruiting
NCT05797246 2026-05-22
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT06796907 2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06955169 2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Suspended
NCT07216703 2026-05-22
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07318558 2026-05-22
TroFuse-021
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07527832 2026-05-22
An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.
Pfizer
Recruiting
NCT04564898 2026-05-20
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT05546879 2026-05-20
Liver-NET1
University Hospital, Grenoble
Phase 1 Active not recruiting
NCT06787612 2026-05-20
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT07500298 2026-05-20
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT00951496 2026-05-19
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT05468359 2026-05-19
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06265688 2026-05-19
First In Human Study of CX-2051 in Advanced Solid Tumors
CytomX Therapeutics
Phase 1 Recruiting
NCT07024784 2026-05-19
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT07359456 2026-05-19
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT04181060 2026-05-18
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05871021 2026-05-18
PRIDE
University Hospital Tuebingen
Phase 2 Recruiting
NCT06083844 2026-05-18
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06783647 2026-05-18
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT06948448 2026-05-18
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting